ClinicalTrials.gg

Program

HS-20136-2

A development code. Also written as “HS-20136-2 injection”.

In Hansoh Pharmaceutical Group's pipeline, T2DM, weight. Its studies are mostly in Obesity, led by Hansoh Pharmaceutical Group.

Furthest: phase 1, since Mar 12, 20262 company-led studies, 2 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hansoh Pharmaceutical Group22 open or runningphase 1since Mar 12, 2026Mar 12, 2026Dec 31, 2026phase 1 · NCT07483437
  • Named in Hansoh Pharmaceutical Group’s own pipeline as HS-20136-2 (T2DM, weight), phase 1, as of Aug 26, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 12, 2026First study: phase 1 study in HealthyFirst studyNCT07483437 · 38 planned · Australia
  2. Jul 16, 2026Phase 1 study in ObesityNCT07716241 · 92 planned · China

Ahead

  1. Dec 31, 2026Primary completion: phase 1 study in HealthyNCT07483437
  2. May 14, 2027Primary completion: phase 1 study in ObesityNCT07716241

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“T2DM, weight”the company's pipeline, read by Claude · source

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07716241Obesity · China1Not yet recruitingMay 14, 202792
NCT07483437Healthy · Australia1Not yet recruitingDec 31, 202638

How it is read

Names in the registry

  • “HS-20136-2”, 2 entries
  • “HS-20136-2 injection”, 1 entry

Codes read as this program: HS201362.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.